Search

Your search keyword '"Borducchi EN"' showing total 39 results

Search Constraints

Start Over You searched for: Author "Borducchi EN" Remove constraint Author: "Borducchi EN" Search Limiters Full Text Remove constraint Search Limiters: Full Text
39 results on '"Borducchi EN"'

Search Results

1. Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial.

2. Ad26.M.Env ZIKV vaccine protects pregnant rhesus macaques and fetuses against Zika virus infection.

3. Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy.

4. Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques.

5. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.

6. Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques.

7. Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates.

8. HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys.

9. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.

10. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.

11. Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques.

12. Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques.

13. Origin of rebound virus in chronically SIV-infected Rhesus monkeys following treatment discontinuation.

14. Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques.

15. Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C.

16. Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN-αβR -/- Mice.

17. Publisher Correction: Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys.

18. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys.

19. Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys.

20. Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys.

21. Fetal Neuropathology in Zika Virus-Infected Pregnant Female Rhesus Monkeys.

22. Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors.

23. Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys.

24. Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys.

25. Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys.

26. Vaccine protection against Zika virus from Brazil.

27. Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques.

28. Transient CD4+ T Cell Depletion Results in Delayed Development of Functional Vaccine-Elicited Antibody Responses.

29. Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization.

30. Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors.

31. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys.

32. Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors.

33. Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimens.

34. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

35. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys.

36. An attenuated Listeria monocytogenes vector primes more potent simian immunodeficiency virus-specific mucosal immunity than DNA vaccines in mice.

37. Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors.

38. Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.

39. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.

Catalog

Books, media, physical & digital resources